Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.

  • Authors:
    • M Indrová
    • J Bubeník
    • J Símová
    • V Vonka
    • S Nemecková
    • L Mendoza
    • M Reinis
  • View Affiliations

  • Published online on: January 1, 2001     https://doi.org/10.3892/ijmm.7.1.97
  • Pages: 97-197
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Murine carcinoma induced by MK 16 cells expressing HPV 16 E6/E7 oncogenes was utilized to examine the therapeutic effect of dendritic cell-based tumour vaccines. Mice carrying 5-day MK 16 tumours were injected peritumorally with either dendritic cells (DC) or DC pulsed with MK 16 tumour lysate. Both the unpulsed and MK 16 lysate-pulsed DC vaccines inhibited growth of the MK 16 transplants, the pulsed DC being more efficient than the unpulsed vaccines. In vitro priming of the effector cell-mediated anti-MK 16 responses by DC pulsed with MK 16 tumour lysate and a synthetic HPV 16 E7(49-57) peptide RAHYNIVTF was compared. The priming activity of the lysate was substantially higher than that of the HPV 16 E7(49-57) peptide; the priming activity was similar to that of a standard moderately immunogenic chemically-induced sarcoma. Taken collectively, these results suggest that DC vaccines pulsed with HPV 16-associated tumour lysates represent a prospective modality for treatment of HPV 16-associated carcinomas.

Related Articles

Journal Cover

January 2001
Volume 7 Issue 1

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Indrová M, Bubeník J, Símová J, Vonka V, Nemecková S, Mendoza L and Reinis M: Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.. Int J Mol Med 7: 97-197, 2001.
APA
Indrová, M., Bubeník, J., Símová, J., Vonka, V., Nemecková, S., Mendoza, L., & Reinis, M. (2001). Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.. International Journal of Molecular Medicine, 7, 97-197. https://doi.org/10.3892/ijmm.7.1.97
MLA
Indrová, M., Bubeník, J., Símová, J., Vonka, V., Nemecková, S., Mendoza, L., Reinis, M."Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.". International Journal of Molecular Medicine 7.1 (2001): 97-197.
Chicago
Indrová, M., Bubeník, J., Símová, J., Vonka, V., Nemecková, S., Mendoza, L., Reinis, M."Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.". International Journal of Molecular Medicine 7, no. 1 (2001): 97-197. https://doi.org/10.3892/ijmm.7.1.97